Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript November 7, 2023 Marinus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.67. Operator: Greetings and welcome to the Marinus Pharmaceuticals’ Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions]. And now, it is my pleasure to introduce your host, Sonya […]
/PRNewswire/ NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving.
/PRNewswire/ Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,.